Premature Birth clinical trials at UC Irvine
4 in progress, 3 open to eligible people
Bevacizumab Treatment For Type 1 ROP
open to eligible people ages up to 6 months
Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Also unknown is the timing and extent of peripheral retinal vascularization after low-dose bevacizumab compared with the standard dose. The current study will evaluate whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP and retinal vessels all in zone I.
Irvine, California and other locations
Caffeine Use in the Management of Preterm Infants
open to all eligible people
This study aims to assess whether extending the duration of caffeine therapy will help preterm infants achieve full oral feeding faster.
Orange, California
Two Year Developmental Follow-up for PREMOD2 Trial (Premature Infants Receiving Milking or Delayed Cord Clamping)
open to eligible people ages 22 months to 42 months
An extension of the PREMOD2 trial, the PREMOD2 Follow-Up trial will evaluate the neurodevelopmental outcomes at 22-26 months corrected age of preterm children who received UCM or DCC. This prospective multi-national randomized controlled trial (RCT) is a two-arm parallel non-inferiority design of two alternative approaches of treatment.
Orange, California and other locations
Early Caffeine and LISA Compared to Caffeine and CPAP in Preterm Infants
Sorry, in progress, not accepting new patients
This study is being conducted to determine whether prophylactic administration of surfactant by the Less Invasive Surfactant Administration (LISA) method reduces the need for mechanical ventilation in the first 72 hours of life when compared to early Continuous Positive Airway Pressure (CPAP) alone.
Irvine, California and other locations
Our lead scientists for Premature Birth research studies include Cherry Uy, MD.
Last updated: